Sonoma Pharmaceuticals, INC 8-K filings

Sonoma Pharmaceuticals has increased the aggregate offering price for its common stock under an At Market Issuance Sales Agreement to $3,641,703.

Sonoma Pharmaceuticals has closed a public offering of common stock and warrants, raising approximately $3.5 million in net proceeds.

Sonoma Pharmaceuticals, Inc. has entered into a significant Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn technology-based products in the United States.

Sonoma Pharmaceuticals announces Dr. Jay Birnbaum's retirement from its Board, replaced by experienced financial executive Ms. Vanessa Jacoby, alongside updates to director compensation.

Sonoma Pharmaceuticals highlights significant revenue growth, improved financial performance, and strategic market expansion in its latest investor presentation.

Sonoma Pharmaceuticals, Inc. announced its annual equity grant to employees, including executive officers and non-employee directors, aimed at retention and recognition.

Sonoma Pharmaceuticals, Inc. announced the termination of Executive Vice President and Chief Operating Officer Bruce Thornton for cause, effective October 18, 2025.

Sonoma Pharmaceuticals, Inc. announced an amended employment agreement for CEO Amy Trombly, increasing her salary and adjusting severance terms, while COO Bruce Thornton will retire and his position will be eliminated.

Sonoma Pharmaceuticals, Inc. released an updated investor presentation showcasing robust revenue growth, improved financial metrics, and significant expansion in product lines and global distribution.

Sonoma Pharmaceuticals, Inc. has entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to potentially sell up to $2,070,463 of common stock.

Sonoma Pharmaceuticals, Inc. announced the results of its annual meeting, including the election of Dr. Jay Birnbaum and the approval of executive compensation and auditor ratification.

Sonoma Pharmaceuticals releases an updated investor presentation highlighting its hypochlorous acid (HOCl) technology and recent business developments.

Sonoma Pharmaceuticals highlights its focus on hypochlorous acid (HOCl) products, global expansion, and diverse applications in its latest investor presentation.

Sonoma Pharmaceuticals amends its Master Supply Agreement with WellSpring Pharmaceutical Corporation to include additional Microcyn technology-based products for sale to large retailers in the United States.

Sonoma Pharmaceuticals has entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of Microcyn technology-based products to large retailers in the United States.

Sonoma Pharmaceuticals has completed its annual equity grant, issuing stock options to non-employee directors and restricted stock units to executive officers.

Sonoma Pharmaceuticals has terminated its exclusive supply and distribution agreement with EMC Pharma, regaining the rights to sell its prescription dermatological and eye care products in the United States.

Sonoma Pharmaceuticals has amended its distribution agreement with Medline Industries, expanding its reach to Canada and including over-the-counter sales in both the US and Canada.

Sonoma Pharmaceuticals has filed a prospectus supplement related to its existing equity distribution agreement, potentially offering up to $835,400 of its common stock.

Sonoma Pharmaceuticals has enacted a 1-for-20 reverse stock split and increased authorized shares to maintain its Nasdaq listing.

Sonoma Pharmaceuticals has filed an 8-K report related to its existing equity distribution agreement with Maxim Group LLC, allowing for the potential sale of up to $1,270,352 of common stock.

Sonoma Pharmaceuticals has entered into a five-year distribution agreement with Medline Industries for its wound care products, effective August 19, 2024.

Sonoma Pharmaceuticals has filed a prospectus supplement related to its existing equity distribution agreement, allowing for the potential sale of up to $434,102 of common stock.

Sonoma Pharmaceuticals' investor presentation showcases its global reach, diverse product portfolio, and growth strategy in the healthcare and skincare markets.

Sonoma Pharmaceuticals released an investor presentation showcasing its global reach, hypochlorous acid technology, and diverse product portfolio across various healthcare sectors.

Sonoma Pharmaceuticals has received an extension until September 16, 2024, to meet Nasdaq's minimum bid price requirement for continued listing.

Sonoma Pharmaceuticals has amended its equity distribution agreement to allow for the sale of up to $785,679 of additional common stock.